A central
line or central venous line is another name for a central venous catheter. It
is a flexible tube that is put into a vein beneath the right side of the
collarbone and led to the superior vena cava, a big vein that leads to the
heart. A central venous catheter is used to administer various fluids, which
can then be conveniently administered into the patients' bodies. Intravenous
fluid, blood transfusions, and chemotherapeutic medicines are among the fluids.
In 2011, the Centers for Disease Control and Prevention (CDC) issued guidelines
for preventing intravascular catheter-related infections, which were updated in
2017. The guideline covers a variety of critical elements related to central
venous catheters, including adequate training for healthcare practitioners who
insert intravascular catheters and staff who are responsible for catheter
surveillance and catheter application site selection.
Global Central Venous Catheter Market
- Impact of the Coronavirus (COVID-19) Pandemic
Over the
projected period, the global
central venous catheter market is expected to be constrained by the
COVID-19 pandemic. For example, a study published in Current Oncology, a
Canadian Cancer Research Journal, in June 2020 evaluated the impact of the
COVID-19 epidemic in China on Stage II and Stage III colon cancer patients
receiving adjuvant chemotherapy treatment.
Furthermore,
the worldwide
central venous catheters market is likely to be hampered by a decline
in the number of blood transfusions. For example, during the COVID-19 pandemic,
extra problems occurred for blood transfusion as a result of lockdown, social
isolation, and fear of blood virus transmission, according to an article
published in the journal Transfusion Medicine and Hemotherapy in November 2021.
Furthermore, the elderly, who gave the majority of blood donations, were among
the most sensitive to the virus, resulting in reduced donations from them,
according to the same source.
Regulatory
authorities are issuing guidance to market participants regarding the
classification of central venous catheters, which is projected to fuel market
expansion throughout the forecast period. For example, the US Food and Drug
Administration (FDA) issued a De Novo classification order for Bluegrass
Vascular Technologies' Surfacer Inside-Out Access Catheter System in 2020. The
technique was created to allow patients with upper body venous occlusions to
gain central venous access so that a catheter may be inserted into the central
venous system.
Comments
Post a Comment